Cargando…

Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine

The patient was 32-year-old man, who received olanzapine for schizophrenia and developed polyuria and thirst without drinking soft-drinks after 4 months. Five months after the initiation of treatment, he developed diabetic ketoacidosis (blood glucose: 490 mg/dL, HbA1c: 15.5%). He was diagnosed with...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwaku, Kenji, Otuka, Fumiko, Taniyama, Matsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348459/
https://www.ncbi.nlm.nih.gov/pubmed/28154279
_version_ 1782514232710922240
author Iwaku, Kenji
Otuka, Fumiko
Taniyama, Matsuo
author_facet Iwaku, Kenji
Otuka, Fumiko
Taniyama, Matsuo
author_sort Iwaku, Kenji
collection PubMed
description The patient was 32-year-old man, who received olanzapine for schizophrenia and developed polyuria and thirst without drinking soft-drinks after 4 months. Five months after the initiation of treatment, he developed diabetic ketoacidosis (blood glucose: 490 mg/dL, HbA1c: 15.5%). He was diagnosed with type 1 diabetes (glutamic acid decarboxylase (GAD)-Ab: 5.6 U/mL, IA-2 Ab: 5.9 U/mL, fasting C-peptide: 0.12 ng/mL) and was put on intensive insulin therapy. At four months after the onset of 1A diabetes, he experienced a honeymoon phase that was sustained until the 40th month of treatment. We hypothesize that the administration of olanzapine to a patient with pre-type 1A diabetes induced marked hyperglycemia and accelerated the onset of type 1A diabetes.
format Online
Article
Text
id pubmed-5348459
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-53484592017-03-24 Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine Iwaku, Kenji Otuka, Fumiko Taniyama, Matsuo Intern Med Case Report The patient was 32-year-old man, who received olanzapine for schizophrenia and developed polyuria and thirst without drinking soft-drinks after 4 months. Five months after the initiation of treatment, he developed diabetic ketoacidosis (blood glucose: 490 mg/dL, HbA1c: 15.5%). He was diagnosed with type 1 diabetes (glutamic acid decarboxylase (GAD)-Ab: 5.6 U/mL, IA-2 Ab: 5.9 U/mL, fasting C-peptide: 0.12 ng/mL) and was put on intensive insulin therapy. At four months after the onset of 1A diabetes, he experienced a honeymoon phase that was sustained until the 40th month of treatment. We hypothesize that the administration of olanzapine to a patient with pre-type 1A diabetes induced marked hyperglycemia and accelerated the onset of type 1A diabetes. The Japanese Society of Internal Medicine 2017-02-01 /pmc/articles/PMC5348459/ /pubmed/28154279 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Iwaku, Kenji
Otuka, Fumiko
Taniyama, Matsuo
Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine
title Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine
title_full Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine
title_fullStr Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine
title_full_unstemmed Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine
title_short Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine
title_sort acute-onset type 1 diabetes that developed during the administration of olanzapine
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348459/
https://www.ncbi.nlm.nih.gov/pubmed/28154279
work_keys_str_mv AT iwakukenji acuteonsettype1diabetesthatdevelopedduringtheadministrationofolanzapine
AT otukafumiko acuteonsettype1diabetesthatdevelopedduringtheadministrationofolanzapine
AT taniyamamatsuo acuteonsettype1diabetesthatdevelopedduringtheadministrationofolanzapine